Triple combination therapy is the administration of obinutuzumab, ibrutinib, and venetoclax in a sequential order. Barbara Eichhorst from the University Hospital Cologne, Cologne, Germany, discusses an interesting Phase I trial in which the triple combination therapy was delivered to patients who have relapsed from chronic lymphocytic leukemia (CLL). From the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Prof. Eichhorst also reports her latest randomised trial using triple combination therapy in high-risk patients with CLL that have TP53 mutation or deletion, comparing the efficacy of this treatment to chemoimmunotherapy.
